Charlene Santos

730 total citations
20 papers, 416 citations indexed

About

Charlene Santos is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charlene Santos has authored 20 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charlene Santos's work include Brain Metastases and Treatment (5 papers), Nanoparticle-Based Drug Delivery (5 papers) and Nanoplatforms for cancer theranostics (5 papers). Charlene Santos is often cited by papers focused on Brain Metastases and Treatment (5 papers), Nanoparticle-Based Drug Delivery (5 papers) and Nanoplatforms for cancer theranostics (5 papers). Charlene Santos collaborates with scholars based in United States and Italy. Charlene Santos's co-authors include William C. Zamboni, C. Ryan Miller, David B. Darr, Andrew T. Lucas, Charles M. Perou, Carey K. Anders, Allison M. Deal, Gina Song, Ryan Bash and Sara O’Neal and has published in prestigious journals such as Nature Communications, PLoS ONE and Cancer Research.

In The Last Decade

Charlene Santos

18 papers receiving 408 citations

Peers

Countries citing papers authored by Charlene Santos

Since Specialization

Citations

This map shows the geographic impact of Charlene Santos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene Santos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene Santos more than expected).

Fields of papers citing papers by Charlene Santos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene Santos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene Santos. The network helps show where Charlene Santos may publish in the future.

Co-authorship network of co-authors of Charlene Santos

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene Santos. A scholar is included among the top collaborators of Charlene Santos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene Santos. Charlene Santos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma 2024 ·Nature Communications ·Le Yu, Yu Deng, Xiaodong Wang, Charlene Santos, Ian J. Davis, H. Shelton Earp, Pengda Liu	4
2	Genome-wide cancer-specific chromatin accessibility patterns derived from archival processed xenograft tumors 2021 ·Genome Research ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), James K. Tsuruta, Sandeep K. Kasoji, Charlene Santos, Paul A. Dayton, Joel S. Parker, Ian J. Davis, Samantha G. Pattenden	4
3	Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model 2021 ·Therapeutic Advances in Medical Oncology ·Lauren Price, (unknown), (unknown), (unknown), Joseph Piscitelli, (unknown), Charlene Santos, Jose Roques, Bentley R. Midkiff, (unknown), David B. Darr, S Chang, William C. Zamboni	5
4	Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer 2020 ·Molecular Cancer Research ·Daniel R. Goulet, (unknown), Jon S. Zawistowski, Samantha M. Bevill, (unknown), (unknown), Noah Sciaky, Darshan Singh, Charlene Santos, Samantha G. Pattenden, Ian J. Davis, Gary L. Johnson	3
5	Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models 2020 ·UNC Libraries ·Mark Ross, Charlene Santos, Bentley R. Midkiff, William C. Zamboni, Charles M. Perou, C. Ryan Miller, Nana Nikolaishvili‐Feinberg, Arlin B. Rogers, Stephanie M. Cohen, (unknown), David B. Darr, Andrew C. Dudley, (unknown), Gina Song, Teresa K. Tarrant	1
6	GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer 2019 ·Molecular Cancer Research ·Samantha M. Bevill, (unknown), Noah Sciaky, Brian T. Golitz, Darshan Singh, Adriana S. Beltrán, Naim U. Rashid, Timothy J. Stuhlmiller, Andrew Hale, Nathaniel J. Moorman, Charlene Santos, Steven P. Angus, Jon S. Zawistowski, Gary L. Johnson	44
7	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models 2019 ·Neuro-Oncology Advances ·Maria J. Sambade, Amanda E.D. Van Swearingen, Marni B. McClure, Allison M. Deal, Charlene Santos, Kaiming Sun, Jing Wang, Keith Mikule, Carey K. Anders	12
8	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer 2017 ·Neuro-Oncology ·Amanda E.D. Van Swearingen, Maria J. Sambade, Marni B. Siegel, Shivani Sud, Robert S. McNeill, Samantha M. Bevill, Xin Chen, Ryan Bash, (unknown), Brian T. Golitz, Charlene Santos, Allison M. Deal, Joel S. Parker, Naim U. Rashid, C. Ryan Miller, Gary L. Johnson, Carey K. Anders	32
9	Abstract 5051: Comparison of microbeam versus conventional broadbeam radiation therapy on tumor delivery enhancement of PEGylated liposomal doxorubicin in a triple negative breast cancer mouse model 2017 ·Cancer Research ·S Chang, (unknown), (unknown), Lauren Price, (unknown), Jose Roques, Charlene Santos, David B. Darr, William C. Zamboni	1
10	Pharmacokinetics and Efficacy of doxorubicin-loaded Plant Virus Nanoparticles in Preclinical Models of Cancer 2017 ·Nanomedicine ·(unknown), (unknown), (unknown), Charlene Santos, (unknown), (unknown), Stefan Franzen, Steven A. Lommel, C. Ryan Miller, Paola A. Gehrig, William C. Zamboni	12
11	Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains 2016 ·Nanomedicine Nanotechnology Biology and Medicine ·Gina Song, Oscar Suzuki, Charlene Santos, Andrew T. Lucas, Tim Wiltshire, William C. Zamboni	10
12	Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models 2016 ·Nanomedicine Nanotechnology Biology and Medicine ·Andrew T. Lucas, (unknown), Allison M. Deal, (unknown), Gina Song, Charlene Santos, William C. Zamboni	14
13	Abstract 3316: The effects of dopamine receptor 2 on breast cancer tumor initiating cells 2016 ·Cancer Research ·Matthew Tegowski, Charlene Santos, Albert S. Baldwin	3
14	Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA -Mutated and BRCA –Wild-Type Triple-Negative Breast Cancer 2015 ·Molecular Cancer Therapeutics ·Olga Karginova, Marni B. Siegel, Amanda E.D. Van Swearingen, Allison M. Deal, Bárbara Adamo, Maria J. Sambade, (unknown), Nana Nikolaishvili‐Feinberg, Ryan Bash, Sara O’Neal, (unknown), Joel S. Parker, Charlene Santos, David B. Darr, William C. Zamboni, Yueh Z. Lee, C. Ryan Miller, Carey K. Anders	53
15	Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer 2015 ·Nanomedicine Nanotechnology Biology and Medicine ·Gina Song, Teresa K. Tarrant, (unknown), David A. Barrow, Charlene Santos, (unknown), Suzan K. Hanna, Ramesh K. Ramanathan, Craig R. Lee, Victoria Bae‐Jump, Paola A. Gehrig, William C. Zamboni	23
16	A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues 2015 ·Journal of Pharmaceutical and Biomedical Analysis ·Andrew T. Lucas, Sara O’Neal, Charlene Santos, (unknown), William C. Zamboni	36
17	Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models 2015 ·Cancer Research ·Amanda E.D. Van Swearingen, Marni B. Siegel, Maria J. Sambade, Shivani Sud, Samantha M. Miller, Grace Silva, Ryan Bash, Charlene Santos, David B. Darr, Brian T. Golitz, Joel S. Parker, C. Ryan Miller, Gary L. Johnson, Carey K. Anders	0
18	Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models 2014 ·Clinical Cancer Research ·Gina Song, David B. Darr, Charlene Santos, Mark Ross, (unknown), (unknown), Bentley R. Midkiff, Stephanie M. Cohen, Nana Nikolaishvili‐Feinberg, C. Ryan Miller, Teresa K. Tarrant, Arlin B. Rogers, Andrew C. Dudley, Charles M. Perou, William C. Zamboni	85
19	Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models 2014 ·Cancer Research ·Amanda E.D. Van Swearingen, Marni B. Siegel, Ryan Bash, Brian T. Golitz, Charlene Santos, David B. Darr, Joel S. Parker, Gary L. Johnson, C. Ryan Miller, Carey K. Anders	0
20	Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer 2013 ·PLoS ONE ·Carey K. Anders, Bárbara Adamo, Olga Karginova, Allison M. Deal, Sumit Rawal, David B. Darr, Allison N. Schorzman, Charlene Santos, Ryan Bash, Tal Kafri, Lisa A. Carey, C. Ryan Miller, Charles M. Perou, Norman E. Sharpless, William C. Zamboni	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact